“New
treatment approaches are successfully providing relief for our patients.
Cubex Audiology is dedicated to staying abreast of new technological
developments and is one of the first UK pilot sites for SoundCure™ Serenade®,”
says Orla Kealy, Audiologist at Cubex.
Over the years we have gone from perceiving tinnitus as a
disease of the ear to understanding it as a disorder of the brain. While it is
still generally believed that damage to the peripheral auditory system is a
necessary factor in triggering tinnitus, recent evidence suggests that tinnitus
is caused by abnormal activities resulting from cortical re-organization.
Originally developed at UC Irvine, S-Tones® are the
foundation of the SoundCure Serenade technology. The approach is to introduce cortically
interesting sounds to positively alter abnormal neural activities for the
purpose of tinnitus suppression. Different from steady-state sounds such as
pure tones and noises, which produce mostly onset and offset responses in the
cortex, the temporally patterned sounds we use, such as amplitude- and frequency-modulated
signals, produce highly synchronized and robust cortical responses.
“Serenade is a complete, FDA cleared sound therapy
solution," adds Orla. "It is simple to use and customized to each patient. The digital
signal processing system is based on the relationship between specific tonal
algorithms and their effects. After a tinnitus evaluation, the Serenade device is
programmed to deliver the sounds most likely to be effective for that
individual. This approach may be used to seek immediate relief, as well as long
term benefit when used as part of an ongoing tinnitus treatment program.”
For more information contact Orla Kealy BSc RHAD on 0207 935 5511 or sign up at www.cubex.co.uk/signup.
Private hearing treatment news: 17 September 2012
